BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

INCOGEN Receives Additional Funding For Cancer Diagnostics Research


10/19/2005 5:10:57 PM

WILLIAMSBURG, Va.--(BUSINESS WIRE)--April 19, 2004--INCOGEN has announced that it received a two-year, $2 Million award from the National Institutes of Health - National Cancer Institute to continue its research program in cancer diagnostics. The research program involves a close collaboration with scientists from the College of William and Mary and clinical researchers from the Eastern Virginia Medical School.

The award is a Phase II follow-on to a previous grant which INCOGEN received from the NIH a year ago. The Phase I award provided funding for INCOGEN and its academic collaborators to develop a pilot project in the analysis of data obtained from surface-enhanced laser desorption ionization (SELDI) mass spectrometry. This approach may provide alternative, highly accurate methods for screening for cancers that currently require invasive diagnoses, such as prostate cancer or leukemia. SELDI was developed by the Fremont, CA-based company Ciphergen, who makes and distributes the instruments used for this research.

"We are delighted to continue working on this important project. The Phase II funding will allow us to continue to take advantage of the world-class expertise in data analysis and experimental research at William and Mary, and also the state-of-the-art proteomics and SELDI work at Eastern Virginia Medical School," said Dr. Maciek Sasinowski, INCOGEN Founder and CEO. "INCOGEN came to Virginia two-and-a-half years ago to foster collaborations among academic institutions in the Commonwealth and to act as the 'glue' between computational science and life science experts. Our current work with W&M and EVMS is a terrific success story of just how fruitful this type of collaboration can be."

Under the award, both institutions will act as subcontractors to INCOGEN. The data will be produced at EVMS and analyzed at both INCOGEN and W&M. The goal of the Phase II research is to develop a ready-to-use, clinical diagnostic software package, based on INCOGEN's highly successful Visual Integrated Bioinformatics Environment (VIBE) software. The new software product will be distributed to clinical researchers involved in diagnostic work.

About INCOGEN:

INCOGEN, Inc. provides state-of-the-art software and industry-leading professional services to scientists involved in pharmaceutical, agricultural and biotechnology research. The suite of INCOGEN tools includes GenePort(R), a web-browser-based information mining and management portal; VIBE(TM), an extensible bioinformatics visual programming and workflow management platform; and HDFR(TM) and Magelan(TM), two image analysis software packages. INCOGEN Professional Services provide scientists with industry-leading technological expertise to assist researchers with every phase of design, development and implementation of their informatics infrastructures. The company is committed to supplying the research community with tools to optimize the analysis, mining, and management of life science data.

Contacts

INCOGEN, Inc. Don Van Dyke, 919-510-8907; Fax, 919-781-7687; info@incogen.com; www.incogen.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES